Analogs of the anti-malaria drug mefloquine have broad-spectrum antifungal activity and are efficacious in a model of disseminated Candida auris infection.

Autor:	Guin S; Department of Chemistry, School of Science and Engineering, Saint Louis University, Saint Louis, Missouri, USA., Montoya MC; Department of Pediatrics, Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA., Wang X; Department of Biochemistry, UT Southwestern Medical Center, Dallas, Texas, USA., Zarnowski R; Department of Medicine, Section of Infectious Disease, University of Wisconsin, Madison, Wisconsin, USA.; Department of Medical Microbiology and Immunology, University of Wisconsin, Madison, Wisconsin, USA., Andes DR; Department of Medicine, Section of Infectious Disease, University of Wisconsin, Madison, Wisconsin, USA.; Department of Medical Microbiology and Immunology, University of Wisconsin, Madison, Wisconsin, USA., Meyers MJ; Department of Chemistry, School of Science and Engineering, Saint Louis University, Saint Louis, Missouri, USA., Williams NS; Department of Medical Microbiology and Immunology, University of Wisconsin, Madison, Wisconsin, USA., Krysan DJ; Department of Pediatrics, Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA.; Department of Molecular Physiology and Biophysics, Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA.
Jazyk:	angličtina
Zdroj:	Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2024 Nov 06; Vol. 68 (11), pp. e0130124. Date of Electronic Publication: 2024 Oct 04.
DOI:	10.1128/aac.01301-24
Abstrakt:	Only three classes of antifungal drugs are currently in clinical use. Here, we report that derivatives of the malarial drug mefloquine have broad-spectrum antifungal activity including difficult-to-treat molds and endemic fungi. Pharmacokinetic and efficacy studies of NSC-4377 indicate that it penetrates the central nervous system and is active against Candida auris in vivo . These data strongly support the further development of mefloquine analogs as a potentially new class of antifungal molecules. Competing Interests: The authors declare no conflict of interest.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu